DBV Stock Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.20 |
| 52 Week High | €4.30 |
| 52 Week Low | €1.10 |
| Beta | 0.76 |
| 1 Month Change | -9.84% |
| 3 Month Change | -33.85% |
| 1 Year Change | -58.62% |
| 3 Year Change | -89.30% |
| 5 Year Change | -93.19% |
| Change since IPO | -86.64% |
Recent News & Updates
Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14
DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 10Recent updates
Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 10Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Dec 01Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Jun 23We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash Wisely
Mar 09Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation
Oct 04DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 06Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash Wisely
Mar 14Will DBV Technologies (EPA:DBV) Spend Its Cash Wisely?
Oct 20We Think Some Shareholders May Hesitate To Increase DBV Technologies S.A.'s (EPA:DBV) CEO Compensation
May 12When Will DBV Technologies S.A. (EPA:DBV) Become Profitable?
May 06DBV Technologies S.A. (EPA:DBV) Analysts Just Trimmed Their Revenue Forecasts By 19%
Mar 31Could The DBV Technologies S.A. (EPA:DBV) Ownership Structure Tell Us Something Useful?
Mar 02Shareholder Returns
| DBV | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -3.2% | -0.06% | -0.2% |
| 1Y | -58.6% | -4.3% | 2.4% |
Return vs Industry: DBV underperformed the French Biotechs industry which returned -4.3% over the past year.
Return vs Market: DBV underperformed the French Market which returned 2.4% over the past year.
Price Volatility
| DBV volatility | |
|---|---|
| DBV Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: DBV's share price has been volatile over the past 3 months.
Volatility Over Time: DBV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 105 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| DBV fundamental statistics | |
|---|---|
| Market cap | €115.45m |
| Earnings (TTM) | -€67.77m |
| Revenue (TTM) | €14.66m |
7.9x
P/S Ratio-1.7x
P/E RatioIs DBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBV income statement (TTM) | |
|---|---|
| Revenue | US$15.73m |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.73m |
| Other Expenses | US$88.45m |
| Earnings | -US$72.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 100.00% |
| Net Profit Margin | -462.40% |
| Debt/Equity Ratio | 0% |
How did DBV perform over the long term?
See historical performance and comparison